"
Team:Goettingen/project overview/therapeutics
From 2014.igem.org
m |
m |
||
| Line 17: | Line 17: | ||
<li>Background | <li>Background | ||
<ul> | <ul> | ||
| - | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview" | + | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview">The global burden of fungal infections</a></li> |
<li><a href="https://2014.igem.org/Team:Goettingen/project_overview/fungal_infections">Fungal infections</a></li> | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/fungal_infections">Fungal infections</a></li> | ||
<li><a href="https://2014.igem.org/Team:Goettingen/project_overview/current_tools">Current diagnostic tools</a></li> | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/current_tools">Current diagnostic tools</a></li> | ||
| Line 26: | Line 26: | ||
<ul> | <ul> | ||
<li><a href="https://2014.igem.org/Team:Goettingen/project_overview/diganosis">Diagnosis</a></li> | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/diganosis">Diagnosis</a></li> | ||
| - | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/therapeutics">Therapeutics</a></li> | + | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/therapeutics"><b>Therapeutics</b></a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
Revision as of 09:33, 15 September 2014
Project
7/11 
Further perspectives
Therapeutics
Our peptides can also be attached to an antimycotic or opsonizing moiety and act as a therapeutic tool. Again, if the specificity of the peptides is high enough at the species level, it can help to reduce the toxicity issues related to broad-spectrum antimycotics. Regarding opsonizing moieties (such as immune tags or complement ligands), they may help the weakened immune system to attack the fungal cells. An interesting option to explore would be to attach the constant region of human IgG3 immunoglobulins, which can elicit the response of macrophages and neutophils antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity.
It's important to mention that because most patients suffering from invasive mycoses are immunocompromised patients, the eventual application of peptides as therapeutic tools has to be concomitant with immunostimulant therapy, preferably by activating the celular response.
